Pfizer-BioNTech’s COVID-19 vaccine was 73 percent effective in
protection of children aged 6 months to 4 years during the period
when the Omicron strain was highly prevalent, Pfizer announced
This is reported by “Trend” with reference to Xinhua.
The vaccine has been approved for emergency use by the US
The Food and Drug Administration for this age group on June 17.
Study participants received either three doses of 3 µg
Pfizer-BioNTech vaccine or placebo. The effectiveness of the vaccine is 73.2
percentage among children from 6 months to 4 years without
evidence of previous infection with COVID-19, according to the results
both companies said.
“Although these results confirm that three 3 µg doses of our
The vaccine against COVID-19 provides young children with a high level of
protection at a time when the Omicron BA.2 strain was high
prevailing with a favorable safety profile, we also develop
Omicron BA.4/BA.5-adapted bivalent vaccine in this age group for
addressing these sublines,” said Ugur Sahin, CEO and co-founder of
Link to the source